Ding Honggang, Zhuang Zhenjie, Xie Jingyi, Huang Haifu, Tao Zhigang, Liu Zhanhua
Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, People's Republic of China.
Onco Targets Ther. 2020 Aug 10;13:7933-7939. doi: 10.2147/OTT.S240775. eCollection 2020.
EGFR-T790M and are the common resistance mechanisms to EGFR-tyrosine kinase inhibitors (TKIs). Standard treatment for the triple mutations of and is still under debate. Herein, we present a case of therapeutic efficacy of osimertinib and dabrafenib plus trametinib on a 63-year-old man with advanced lung adenocarcinoma. This patient reached a remarkable progression-free survival of 9 months without any serious adverse reaction. At the progression of the disease, mutation in cis was detected by liquid biopsy. Subsequently, brigatinib with cetuximab was administered but no curative effect was observed. Then, therapy was changed to apatinib combined with osimertinib. The subsequent CT scan showed that the lesions reached stable disease (SD), and the survival benefit has been evaluated. This case showed that the combination treatment of osimertinib and dabrafenib plus trametinib might be a great treatment option for NSCLC patients with triple mutations ().
表皮生长因子受体-苏氨酸790甲硫氨酸（EGFR-T790M）以及（此处原文缺失相关内容）是对表皮生长因子受体-酪氨酸激酶抑制剂（TKIs）常见的耐药机制。对于（此处原文缺失相关内容）和（此处原文缺失相关内容）三重突变的标准治疗仍存在争议。在此，我们报告一例奥希替尼以及达拉非尼联合曲美替尼治疗一名63岁晚期肺腺癌男性患者的疗效。该患者达到了9个月显著的无进展生存期且无任何严重不良反应。在疾病进展时，通过液体活检检测到顺式（此处原文缺失相关内容）突变。随后，给予布加替尼联合西妥昔单抗，但未观察到疗效。然后，治疗改为阿帕替尼联合奥希替尼。随后的CT扫描显示病灶达到疾病稳定（SD），并评估了生存获益。该病例表明，奥希替尼以及达拉非尼联合曲美替尼的联合治疗可能是具有三重突变（此处原文缺失相关内容）的非小细胞肺癌患者的一种很好的治疗选择。
